Nordicus' Net Loss Widens to $2.7M Amid R&D Push, Board Expansion

TL;DR

**NORD is burning cash with zero revenue, making it a highly speculative bet on preclinical biotech — avoid unless you're a high-risk gambler.**

AI Summary

Nordicus Partners Corp (NORD) reported a significant increase in net loss for the six months ended September 30, 2025, reaching $2,718,360, a substantial rise from the $758,954 net loss in the same period of 2024. This was primarily driven by a 'Change in fair value of investment' expense of $675,000 in 2025, compared to zero in 2024, and a substantial increase in operating expenses from $768,064 in 2024 to $2,043,364 in 2025. Revenue remained negligible at $0 for the six months ended September 30, 2025, down from $2,500 in 2024. Cash increased significantly to $242,155 at September 30, 2025, from $19,914 at March 31, 2025, largely due to $2,419,220 in proceeds from common stock issuance. The company's total assets grew to $75,882,821 from $70,246,329, with 'In-process research and development' increasing by $3,694,801 to $46,402,880. Nordicus continues its strategy as a business accelerator for Nordic life sciences companies, with a portfolio including Orocidin A/S, Bio-Convert A/S, and NoviThera ApS, all preclinical-stage biotechnology companies. The company also expanded its board, appointing Torben S. Jensen, Kim T. Mcke, and Andrew J. Ritter on August 7, 2025.

Why It Matters

Nordicus' substantial increase in net loss and operating expenses, coupled with zero revenue, signals a high-risk, early-stage investment. While the growth in R&D assets and cash from stock issuance indicates ongoing investment in its life sciences portfolio, investors should be wary of the lack of revenue generation. The competitive landscape in biotechnology is intense, and Nordicus' preclinical-stage companies face a long, uncertain path to market. Employees and customers of its portfolio companies might see continued investment, but the broader market will likely view NORD as a speculative play until tangible commercial progress is demonstrated.

Risk Assessment

Risk Level: high — The company reported a net loss of $2,718,360 for the six months ended September 30, 2025, with zero revenue, indicating a complete lack of commercial operations. Operating expenses surged to $2,043,364, more than double the prior year, driven by increased officer compensation, professional fees, and R&D. This significant cash burn without any revenue generation points to substantial operational and financial risk.

Analyst Insight

Investors should exercise extreme caution and consider NORD a highly speculative investment. Given the zero revenue and increasing losses, potential investors should wait for clear signs of commercialization or significant clinical trial progress from its portfolio companies before considering an investment. Existing investors should re-evaluate their risk tolerance.

Financial Highlights

debt To Equity

0.17

revenue

$0

operating Margin

N/A

total Assets

$75,882,821

total Debt

$11,215,508

net Income

-$2,718,360

eps

N/A

gross Margin

N/A

cash Position

$242,155

revenue Growth

-100.0%

Revenue Breakdown

Key Numbers

• $2,718,360 — Net Loss (Increased from $758,954 in prior year period)
• $0 — Revenue (No revenue generated for the six months ended September 30, 2025)
• $2,043,364 — Total Operating Expenses (Increased from $768,064 in prior year period)
• $675,000 — Change in fair value of investment (New expense contributing to net loss)
• $242,155 — Cash at September 30, 2025 (Increased from $19,914 at March 31, 2025)
• $2,419,220 — Proceeds from issuance of common stock (Primary source of cash inflow)
• $46,402,880 — In-process research and development (Increased by $3,694,801 from March 31, 2025)
• 18,566,360 — Common Stock Outstanding (As of November 12, 2025)
• $75,882,821 — Total Assets (Increased from $70,246,329 at March 31, 2025)
• $1,250,000 — Investment in Mag Mile Capital, Inc. (Decreased from $1,925,000 at March 31, 2025)

Key Players & Entities

• Nordicus Partners Corp (company) — registrant
• Orocidin A/S (company) — preclinical-stage biotechnology company
• Bio-Convert A/S (company) — preclinical-stage biotechnology company
• NoviThera ApS (company) — preclinical-stage biotechnology company
• Mag Mile Capital, Inc. (company) — investment interest
• Allan Wehnert (person) — CEO of Orocidin A/S, Bio-Convert A/S, and NoviThera ApS
• Torben S. Jensen (person) — appointed director
• Kim T. Mcke (person) — appointed director
• Andrew J. Ritter (person) — appointed director
• SEC (regulator) — Securities and Exchange Commission

FAQ

Risk Factors

• Increasing Net Loss [high — financial]: The company reported a net loss of $2,718,360 for the six months ended September 30, 2025, a significant increase from $758,954 in the same period of 2024. This was driven by a new $675,000 expense from 'Change in fair value of investment' and a substantial rise in operating expenses.
• Surge in Operating Expenses [high — operational]: Total operating expenses more than doubled from $768,064 in the six months ended September 30, 2024, to $2,043,364 in the same period of 2025. Key drivers include officer compensation, professional fees, and general and administrative costs.
• Dependence on Equity Financing [medium — financial]: The company's cash position increased significantly to $242,155 from $19,914 due to $2,419,220 in proceeds from common stock issuance. This highlights a reliance on equity financing to fund operations and development.
• Preclinical Stage Investments [medium — operational]: The company's strategy involves accelerating Nordic life sciences companies, with a portfolio of preclinical-stage biotechnology companies. Significant investment in 'In-process research and development' ($46,402,880) indicates substantial upfront costs with uncertain future returns.
• Declining Investment Value [low — financial]: The 'Investment in Mag Mile Capital, Inc.' decreased from $1,925,000 at March 31, 2025, to $1,250,000 at September 30, 2025, indicating a potential impairment or sale of this asset.

Industry Context

Nordicus Partners Corp operates as a business accelerator focused on Nordic life sciences companies. The industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies in this sector often rely on substantial external funding to advance preclinical and clinical development, with a high rate of failure but potential for significant returns upon successful commercialization.

Regulatory Implications

As a company investing in life sciences, Nordicus Partners Corp and its portfolio companies are subject to stringent regulatory oversight from bodies like the FDA and EMA. Delays in regulatory approvals or changes in regulations can significantly impact development timelines and market access, posing a risk to investment value.

What Investors Should Do

1. Monitor operating expense growth closely.
2. Evaluate the strategy for 'In-process research and development'.
3. Assess the impact of equity issuances on dilution.
4. Scrutinize the 'Change in fair value of investment' expense.

Key Dates

• 2025-09-30: Six months ended September 30, 2025 — Reported a net loss of $2,718,360 and total operating expenses of $2,043,364, with zero revenue.
• 2025-08-07: Board Expansion — Appointment of Torben S. Jensen, Kim T. Mcke, and Andrew J. Ritter to the board, potentially signaling a strategic shift or increased governance.
• 2025-03-31: Balance Sheet Date — Cash position was $19,914, and total assets were $70,246,329.

Glossary

In-process research and development

Costs incurred for research and development activities that have not yet reached technological feasibility. These are often significant for companies in early-stage development. (Represents a substantial asset ($46,402,880) and a key area of investment for Nordicus Partners Corp.)

Change in fair value of investment

The unrealized gain or loss resulting from changes in the market value of an investment during a reporting period. (A new expense of $675,000 in the current period significantly contributed to the increased net loss.)

Accumulated deficit

The total net losses of a company that have not been offset by net income since its inception. (Indicates the company has historically incurred more losses than profits, with a deficit of $49,503,208 as of September 30, 2025.)

Goodwill

An intangible asset that arises when a company acquires another company for a price greater than the fair value of its net identifiable assets. (Represents a significant intangible asset on the balance sheet, increasing to $27,696,030.)

Year-Over-Year Comparison

For the six months ended September 30, 2025, Nordicus Partners Corp reported a substantial increase in net loss to $2,718,360 from $758,954 in the prior year period. This deterioration was driven by a significant rise in total operating expenses from $768,064 to $2,043,364, coupled with a new $675,000 expense related to the change in fair value of investments. Revenue remained negligible, falling from $2,500 to $0. Total assets grew to $75,882,821, largely due to an increase in 'In-process research and development' and proceeds from stock issuance, which also boosted the cash position significantly.

Key Financial Figures

• $0.001 — Section 12(g) of the Act: Common Stock, $0.001 par value per share Indicate by check

Filing Documents

• form10-q.htm (10-Q) — 860KB
• ex31-1.htm (EX-31.1) — 12KB
• ex31-2.htm (EX-31.2) — 12KB
• ex32-1.htm (EX-32.1) — 12KB
• 0001493152-25-023246.txt ( ) — 4805KB
• nord-20250930.xsd (EX-101.SCH) — 35KB
• nord-20250930_cal.xml (EX-101.CAL) — 41KB
• nord-20250930_def.xml (EX-101.DEF) — 194KB
• nord-20250930_lab.xml (EX-101.LAB) — 311KB
• nord-20250930_pre.xml (EX-101.PRE) — 266KB
• form10-q_htm.xml (XML) — 655KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 20 Item 3

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 27 Item 4

Controls and Procedures

Controls and Procedures 27 PART II OTHER INFORMATION 28 Item 1.

Legal Proceedings

Legal Proceedings 28 Item 1A.

Risk Factors

Risk Factors 28 Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 28 Item 3 Defaults Upon Senior Securities 28 Item 4 Mine Safety Disclosures 28 Item 5 Other Information 28 Item 6 Exhibits 28

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Unaudited Financial

Item 1. Unaudited Financial NORDICUS PARTNERS CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS September 30, 2025 March 31, 2025 (unaudited) ASSETS Current assets: Cash $ 242,155 $ 19,914 Prepaid expenses and other current assets 242,199 37,656 Total current assets 484,354 57,570 In-process research and development 46,402,880 42,708,079 Property, Plant, and Equipment 7,730 — Intangible assets 3,103 — Goodwill 27,696,030 25,490,751 Investment in Mag Mile Capital, Inc. 1,250,000 1,925,000 Other assets 38,724 64,929 Total assets $ 75,882,821 $ 70,246,329 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable and accrued expenses $ 1,006,875 $ 1,062,661 Total current liabilities 1,006,875 1,062,661 Deferred tax liability 10,208,633 9,318,414 Total liabilities 11,215,508 10,381,075 Commitments and contingencies — — Stockholders' equity: Preferred stock, Series A Junior; $ 0.001 par value; 500,000 shares authorized; no shares issued and outstanding — — Preferred stock, undesignated; $ 0.001 par value; 4,500,000 shares authorized; no shares issued and outstanding — — Preferred stock, value — — Common Stock; $ 0.001 par value; 50,000,000 shares authorized; 18,399,002 and 17,252,502 shares issued and outstanding at September 30, 2025 and March 31, 2025, respectively 18,399 17,253 Treasury stock; 154 shares at cost ( 30,328 ) ( 30,328 ) Additional paid-in capital 108,603,410 106,047,792 Accumulated other comprehensive income 5,579,040 615,385 Accumulated deficit ( 49,503,208 ) ( 46,784,848 ) Total stockholders' equity 64,667,313 59,865,254 Total liabilities and stockholders' equity $ 75,882,821 $ 70,246,329 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 3 NORDICUS PARTNERS CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERA

View Full Filing

View this 10-Q filing on SEC EDGAR